Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | LYN | P07948 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FER | P16591 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31273681 | 1.00 | MYC (0.45) | MYCL3MBTL1ADORA2AADORA1MAPK1 | |
| SCHEMBL19909019 | 0.96 | MYC (0.43) | MYCL3MBTL1ADORA2AADORA1MAPK1 | |
| SCHEMBL19909207 | 0.92 | MYC (0.51) | MYCL3MBTL1ADORA2AADORA1MAPK1 | |
| SCHEMBL22563446 | 0.91 | ABCG2 (0.43) | MYCL3MBTL1ADORA2AADORA1MAPK1 | |
| SCHEMBL22562513 | 0.91 | ADORA1 (0.42) | MYCL3MBTL1ADORA2AADORA1MAPK1 | |
| SCHEMBL19909399 | 0.91 | ALDH1A3 (0.47) | MYCL3MBTL1ADORA2AADORA1MAPK1 | |
| SCHEMBL21278857 | 0.90 | ABCG2 (0.45) | L3MBTL1ADORA2AADORA1MAPK1ABCG2 | |
| SCHEMBL31272961 | 0.90 | ABCG2 (0.45) | L3MBTL1ADORA2AADORA1MAPK1ABCG2 | |
| SCHEMBL19909211 | 0.89 | MYC (0.43) | MYCL3MBTL1ADORA2AADORA1MAPK1 | |
| SCHEMBL19908979 | 0.89 | MYC (0.43) | MYCL3MBTL1ADORA2AADORA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11588114-B2 | Organic molecules for use in optoelectronic devices | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-02-21 | — | — | US | disclosed |
| US-20200212316-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2020-07-02 | — | — | US | disclosed |
| US-10665792-B2 | Organic molecules for use in optoelectronic devices | CYNORA GMBH (DE) | 2020-05-26 | — | — | US | disclosed |
| US-20180062085-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-03-01 | — | — | US | disclosed |
| EP-3287451-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2018-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200212316-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | OR10J3, OPRM1, OR51E2 | MYC 1697/4885L3MBTL1 4685/4885ADORA2A 3726/4885 |
| US-10665792-B2 | Organic molecules for use in optoelectronic devices | OR10J3, CFD, AOX1 | MYC 1636/4885L3MBTL1 3886/4885ADORA2A 4758/4885 |
| US-11588114-B2 | Organic molecules for use in optoelectronic devices | OR10J3, OPRM1, OR51E2 | MYC 1697/4885L3MBTL1 4685/4885ADORA2A 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.